Read the latest news about Light Chain Bioscience
New publication in Frontiers
Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody
New publication : Development and characterization of NILK-2301
A novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers
7th Annual Immuno-Oncology Summit Europe 2023
Antibody Engineering & Therapeutics Europe- Sara Majocchi -
Two Light chain Bioscience presentations at Antibody Engineering & Therapeutics Europe
Antibody Engineering & Therapeutics Europe - Nicolas Fischer & Sara Majocchi -
PEGS Boston – Advancing Bispecific Antibodies and Combination Therapy to the Clinic
19th annual PEGS Boston - Nicolas Fischer -
AACR-2023 NI-2901 (CD47xPD-L1) & NI-3201 (CD28xPD-L1) bispecific antibodies
AACR Annual Meeting 2023 - Walter Ferlin & Xavier Chauchet -
CD28 bispecific antibodies to be presented at PEGS Europe
14th annual PEGS Europe - Sara Majocchi -
SITC 2022, NI-2901 bispecific antibody poster presentation
37th Annual Meeting & Pre-Conference Programs (SITC)
AACR-2022 NI-2601 & NI-2901 CD47xPD-L1 bispecific antibodies
AACR Annual Meeting 2022 - Xavier Chauchet -
AACR-2022 NI-3201 CD28 bispecific antibody platform
AACR Annual Meeting 2022 - Sara Majocchi -
Upcoming conferences - March 2022
We are looking forward to meeting you in person at the follwing events.
SITC 2021, NI-2601 & NI-2901 bispecific antibody programs
36th Annual Meeting & Pre-Conference Programs (SITC)
Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients
Our partner Edesa Biotech announced positive Phase 2 Data for the licensed anti-TLR4 monoclonal antibody in hospitalized COVID-19 patients
